| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
MR Research Centre, Aarhus University Hospital, Skejby Sygehus, 8200 Århus N, Denmark [F. U. N., P. D., H. S-J., R. J. M.]; Instrument Centre for Solid-State NMR Spectroscopy, Chemistry Institute [P. D.] and Danish Cancer Society Department of Experimental Clinical Oncology [L. B., J. O., M. R. H.], Aarhus University, 8000 Århus C, Denmark; and Gray Laboratory Cancer Research Trust, Northwood, Middlesex HA6 2JR, United Kingdom [R. J. M.]
The rate of conversion of D-[1-13C]glucose into [3-13C]lactate (apparent glycolytic rate) has been determined in C3H murine mammary carcinomas in vivo using tumor-selective 13C nuclear magnetic resonance spectroscopy with 1H-13C cross-polarization. Under conditions of acute hypoxia induced by breathing carbon monoxide at 660 ppm, the apparent glycolytic rate was 0.0239 ± 0.0019 min-1. The proportion of 13C label incorporated into [4-13C]glutamate (measured in tumor extracts) was 25-fold lower than that incorporated into [3-13C]lactate, reflecting a very limited oxidative metabolism during this hypoxic episode. For animals breathing air or carbogen (95% O2 + 5% CO2), the calculated glycolytic rates were correspondingly lower (0.0160 ± 0.0021 min-1 and 0.0050 ± 0.0011 min-1, respectively). Although 13C labeling of glutamate at C4 was still an order of magnitude lower than that for lactate at C3 (11-fold for air and 9-fold for carbogen), these ratios did show a greater degree of oxidative metabolism than that seen in animals breathing carbon monoxide at 660 ppm. The marked difference in apparent glycolytic rate for this tumor model between well-oxygenated and hypoxic conditions demonstrates a substantial Pasteur effect (inhibition of glycolysis by oxygen). Dynamic 13C nuclear magnetic resonance spectroscopy provides a noninvasive estimate of tumor glycolysis that can be used to evaluate the relationship between oxygenation and energy metabolism, and this has potential consequences for the sensitivity of hypoxic cells to treatment and their ability to promote angiogenesis.
This article has been cited by other articles:
![]() |
H. Poptani, N. Bansal, W. T. Jenkins, D. Blessington, A. Mancuso, D. S. Nelson, M. Feldman, E. J. Delikatny, B. Chance, and J. D. Glickson Cyclophosphamide Treatment Modifies Tumor Oxygenation and Glycolytic Rates of RIF-1 Tumors: 13C Magnetic Resonance Spectroscopy, Eppendorf Electrode, and Redox Scanning Cancer Res., December 15, 2003; 63(24): 8813 - 8820. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Kunz-Schughart and J. P. Freyer Phosphorous metabolites and steady-state energetics of transformed fibroblasts during three-dimensional growth Am J Physiol Cell Physiol, October 1, 2002; 283(4): C1287 - C1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rivenzon-Segal, R. Margalit, and H. Degani Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo 13C MRS Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E623 - E630. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |